About Human Vasoactive Intestinal Peptide Receptor 1 (VIPR1/VPAC1) Stable Cell Line

Vasoactive Intestinal Peptide Receptor 1 (VIPR1), also known as VPAC1 receptor, is a Class B G protein-coupled receptor (GPCR) that binds the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). VIPR1 is widely expressed throughout the body, including the gastrointestinal tract, lungs, immune cells, liver, pancreas, cardiovascular tissues, and central nervous system. Upon ligand binding, VIPR1 primarily couples to Gs proteins, leading to activation of adenylate cyclase, elevation of intracellular cAMP levels, and regulation of downstream signaling pathways involved in cellular communication, immune regulation, secretion, and smooth muscle relaxation.

VIPR1 plays important roles in maintaining physiological homeostasis through its effects on gastrointestinal function, pulmonary physiology, immune responses, circadian rhythms, and neuroendocrine regulation. Activation of VIPR1 stimulates smooth muscle relaxation, vasodilation, exocrine secretion, and anti-inflammatory signaling. The receptor is particularly important in regulating intestinal fluid secretion, airway function, and immune cell activity. Dysregulation of VIP-VIPR1 signaling has been implicated in inflammatory diseases, asthma, pulmonary disorders, autoimmune conditions, gastrointestinal dysfunction, and certain cancers. As a result, VIPR1 has emerged as an important therapeutic target for immunology, respiratory disease, gastrointestinal disorders, and neuroendocrine research.

eEnzyme's Human VIPR1 Stable Cell Line provides a reliable and reproducible cellular platform for investigating VIPR1-mediated signaling pathways and evaluating receptor-targeted therapeutics. The cell line enables quantitative assessment of VIP analogs, PACAP analogs, agonists, antagonists, antibodies, and novel receptor modulators through cAMP assays, reporter gene assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, ligand profiling, potency determination, lead optimization, and high-throughput screening applications supporting inflammation, respiratory disease, and neuroendocrine drug discovery programs.

Applications of the VIPR1 Stable Cell Line

• VIPR1 receptor pharmacology studies
• VIP and PACAP signaling investigations
• Agonist and antagonist screening
• Inflammation and immunology research
• Respiratory disease and asthma studies
• Gastrointestinal physiology research
• cAMP and GPCR functional assays
• High-throughput screening applications

Biological Significance of VIPR1

VIPR1 is a key mediator of vasoactive intestinal peptide signaling and regulates numerous physiological processes across multiple organ systems. Activation of VIPR1 promotes anti-inflammatory and immunomodulatory responses, helping maintain immune homeostasis and limit excessive inflammatory reactions. In the gastrointestinal tract, VIPR1 regulates smooth muscle relaxation, fluid secretion, and digestive function. In the respiratory system, VIPR1 signaling contributes to bronchodilation and airway protection. The receptor also participates in cardiovascular regulation, circadian rhythm control, neuronal signaling, and endocrine communication. Because of its broad biological functions and therapeutic relevance in inflammatory, respiratory, gastrointestinal, and neuroendocrine disorders, VIPR1 remains an important target for translational research and GPCR-focused drug discovery. The VIPR1 Stable Cell Line provides a valuable tool for studying receptor biology and advancing the development of next-generation VIPR1-targeted therapeutics.